Holen Sie sich die Stockscreener-App
15.60
4.65%
-0.76
Handel nachbörslich:
15.75
0.15
+0.96%
Schlusskurs vom Vortag:
$16.36
Offen:
$16.01
24-Stunden-Volumen:
1.55M
Relative Volume:
0.49
Marktkapitalisierung:
$975.46M
Einnahmen:
$16.10M
Nettoeinkommen (Verlust:
$-198.97M
KGV:
-4.4816
EPS:
-3.4809
Netto-Cashflow:
$-183.99M
1W Leistung:
+2.23%
1M Leistung:
-8.85%
6M Leistung:
-71.28%
1J Leistung:
+14.29%
1-Tages-Spanne:
$15.45
$16.15
1-Wochen-Bereich:
$14.95
$17.72
52-Wochen-Spanne:
$7.76
$71.50
Uniqure N V Stock (QURE) Company Profile
Firmenname
Uniqure N V
Sektor
Branche
Telefon
1-339-970-7000
Adresse
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
15.60 | 1.02B | 16.10M | -198.97M | -183.99M | -3.4809 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-11 | Hochstufung | Mizuho | Neutral → Outperform |
| 2026-03-09 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | Herabstufung | Mizuho | Outperform → Neutral |
| 2026-03-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | Eingeleitet | Wolfe Research | Peer Perform |
| 2026-01-28 | Eingeleitet | Barclays | Equal Weight |
| 2025-11-04 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Hochstufung | Mizuho | Neutral → Outperform |
| 2025-04-01 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2024-12-10 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-02-29 | Herabstufung | Goldman | Buy → Neutral |
| 2023-12-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-17 | Hochstufung | UBS | Neutral → Buy |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-21 | Eingeleitet | UBS | Neutral |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-01 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-11-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-11 | Eingeleitet | Berenberg | Buy |
| 2020-11-09 | Eingeleitet | Jefferies | Buy |
| 2020-11-04 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-08-25 | Eingeleitet | Raymond James | Strong Buy |
| 2020-07-31 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-06-25 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Eingeleitet | Cowen | Outperform |
| 2019-12-03 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | Credit Suisse | Outperform |
| 2019-10-11 | Eingeleitet | Stifel | Buy |
| 2019-09-25 | Eingeleitet | Bernstein | Outperform |
| 2019-09-12 | Eingeleitet | Mizuho | Buy |
| 2019-07-30 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-07-08 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Uniqure N V Aktie (QURE) Neueste Nachrichten
Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming DeadlinesQURE - PR Newswire
UNIQURE N.V. (QURE) SHAREHOLDER ALERT Bernstein Liebhard - GlobeNewswire
QURE stock crashes 32% in a week: Here's what you should know - MSN
uniQure Shareholder Alert: ClaimsFiler Reminds Investors - GlobeNewswire
uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V.QURE - ChartMill
QURE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - marketscreener.com
Levi & Korsinsky Reminds uniQure N.V. Investors of the Pending C - GuruFocus
Levi & Korsinsky Reminds uniQure N.V. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 13, 2026QURE - PR Newswire
Chardan Capital maintains uniQure NV (QURE) buy recommendation - MSN
QURE Shareholder Alert: uniQure N.V. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm - Sahm
uniQure Faces Securities Fraud Lawsuit After FDA Approval Delay - National Today
uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - GlobeNewswire Inc.
Gartner, Inc. Securities Fraud Class Action Result of Reduced Guidance Disclosure and 48% Stock Decline - GlobeNewswire Inc.
Driven Brands Holdings Inc. Securities Fraud Class Action Result of Erroneous Financial Statements and 39% Stock Decline - GlobeNewswire Inc.
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - GlobeNewswire Inc.
uniQure N.V. (QURE) Securities Fraud Class Action Lawsuit Filed; April 13, 2026, Lead Plaintiff Deadline - ChartMill
Liquidity Mapping Around (QURE) Price Events - Stock Traders Daily
uniQure Investors Sue Company Over Huntington’s Disease Drug Study Claims - TipRanks
UNIQURE N.V. (QURE) Berger Montague Advises Investors to Inquire About a Securities Fraud Class Action - marketscreener.com
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
Holzer & Holzer, LLC Reminds Investors of April 13, 2026 - GlobeNewswire
UniQure NV (NASDAQ:QURE) Q4 2025 earnings call transcript - MSN
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit - ChartMill
Barclays Maintains uniQure (QURE) Rating, Lowers Price Target | QURE Stock News - GuruFocus
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 13, 2026 in uniQure Lawsuit – QURE - GlobeNewswire
uniQure (NASDAQ:QURE) Shares Down 4.9% After Analyst Downgrade - MarketBeat
Barclays Maintains uniQure (QURE) Rating, Lowers Price Target | - GuruFocus
QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of uniQure N.V. Investors - GlobeNewswire
QURE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - Sahm
ROSEN, SKILLED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before ... - Bluefield Daily Telegraph
ROSEN, SKILLED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
uniQure N.V. (QURE) Class Action Lawsuit: Investors Face April 13, 2026, Deadline - The Globe and Mail
UniQure surges following departure of key FDA official - MSN
Market Review: What are the analyst revisions for JPMPRPCIs uniQure NV stock a good investment in YEARDividend Hike & Growth Focused Entry Point Reports - baoquankhu1.vn
Investment Recap: Can uniQure NV continue delivering strong returnsMarket Activity Summary & Reliable Momentum Entry Alerts - baoquankhu1.vn
NASDAQ: QURE: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE) - The Globe and Mail
QURE DEADLINE NOTICE: uniQure N.V. Investors Encouraged to Contact Kirby McInerney LLP By April 13, 2026 - ACCESS Newswire
uniQure Faces Investor Lawsuit Reminder - Intellectia AI
uniQure N.V. stock surges on positive Phase 1/ 2 data for AMT-130 in Huntington's disease - AD HOC NEWS
QURE SHAREHOLDER NOTICE: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of "Distorted" Data - PR Newswire
Energy Moves: Does uniQure NV have strong fundamentals2026 Volume Leaders & Reliable Price Breakout Signals - baoquankhu1.vn
uniQure N.V. (QURE) Securities Fraud Class Action Lawsuit - GlobeNewswire
QURE INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026 - TMX Newsfile
uniQure N.V. $QURE Shares Sold by JPMorgan Chase & Co. - MarketBeat
uniQure N.V. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights - Benzinga
QURE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” Data - GlobeNewswire
QURE ALERT: Hagens Berman Updates uniQure (QURE) - GlobeNewswire
QURE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” Data - GlobeNewswire Inc.
Kessler Topaz Meltzer & Check, LLP Filed a Securities Fraud Class Action Lawsuit Against uniQure N.V. (QURE); April 13, 2026, Lead Plaintiff Deadline – Company AnnouncementFT.com - Financial Times
Finanzdaten der Uniqure N V-Aktie (QURE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.04%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):